Management of hepatocellular carcinoma in Asia: consensus statement from the Asian Oncology Summit 2009

The Lancet Oncology

Volumn 10, Issue 11, 2009, Pages 1111-1118

  Poon, Donald ^a,b   Anderson, Benjamin O ^c   Chen, Li Tzong ^d   Tanaka, Koichi ^e   Lau, Wan Yee ^f   Van Cutsem, Eric ^g   Singh, Harjit ^h   Chow, Wan Cheng ⁱ   Ooi, London Lucien ^a,b,i   Chow, Pierce ^b,i   Khin, Maung Win ^j   Koo, Wen Hsin ^a,b  

^a DIVISION OF MEDICAL ONCOLOGY   (Singapore)

^b DUKE NUS MEDICAL SCHOOL   (Singapore)

^c UNIVERSITY OF WASHINGTON SCHOOL OF MEDICINE   (United States)

^d NATIONAL HEALTH RESEARCH INSTITUTES   (Taiwan)

^e INSTITUTE OF BIOMEDICAL RESEARCH AND INNOVATION   (Japan)

^f CHINESE UNIVERSITY OF HONG KONG   (Hong Kong)

^g UNIVERSITY HOSPITALS LEUVEN   (Belgium)

^h Selayang Hospital   (Malaysia)

ⁱ SINGAPORE GENERAL HOSPITAL   (Singapore)

^j Yangon GI and Liver Centre   (Myanmar)

more..

Author keywords

[No Author keywords available]

Indexed keywords

INTERFERON; IODINATED POPPYSEED OIL; LAMIVUDINE; PEGINTERFERON; PEGINTERFERON ALPHA2A; PLACEBO; RETINOID; RIBAVIRIN; SORAFENIB;

ADJUVANT THERAPY; ASIA; CANCER ADJUVANT THERAPY; CANCER EPIDEMIOLOGY; CANCER RADIOTHERAPY; CANCER STAGING; CHEMOEMBOLIZATION; CLINICAL TRIAL; COMPUTER ASSISTED TOMOGRAPHY; ECHOGRAPHY; HEALTH CARE DELIVERY; HEALTH EDUCATION; HEPATITIS B; HEPATITIS C; HUMAN; LIVER CELL CARCINOMA; LIVER CIRRHOSIS; LIVER RESECTION; LIVER TRANSPLANTATION; NUCLEAR MAGNETIC RESONANCE IMAGING; PRACTICE GUIDELINE; PRIORITY JOURNAL; PUBLIC HEALTH; RADIOFREQUENCY ABLATION; RESOURCE ALLOCATION; REVIEW; VACCINATION;

ANTINEOPLASTIC AGENTS; ANTIVIRAL AGENTS; ASIA; CARCINOMA, HEPATOCELLULAR; CATHETER ABLATION; CHEMOEMBOLIZATION, THERAPEUTIC; CHEMOTHERAPY, ADJUVANT; CONGRESSES AS TOPIC; COST-BENEFIT ANALYSIS; DEVELOPING COUNTRIES; DIGESTIVE SYSTEM SURGICAL PROCEDURES; DRUG COSTS; EARLY DETECTION OF CANCER; EVIDENCE-BASED MEDICINE; GUIDELINE ADHERENCE; HEALTH CARE COSTS; HEALTH SERVICES ACCESSIBILITY; HEALTHCARE DISPARITIES; HEPATECTOMY; HEPATITIS B VACCINES; HEPATITIS B, CHRONIC; HEPATITIS C, CHRONIC; HUMANS; LIVER NEOPLASMS; LIVER TRANSPLANTATION; MEDICAL ONCOLOGY; NEOADJUVANT THERAPY; NEOPLASM STAGING; PREDICTIVE VALUE OF TESTS; PREVENTIVE HEALTH SERVICES; RADIOTHERAPY, ADJUVANT; RISK FACTORS; TREATMENT OUTCOME;

EID: 71249126197     PISSN: 14702045     EISSN: None     Source Type: Journal    
DOI: 10.1016/S1470-2045(09)70241-4     Document Type: Review

References (77)

1. International Agency for Cancer Research. GLOBCAN 2002. http://www-dep.iarc.fr (accessed March 18, 2009).
2. Chen C.J., Wang L.Y., Lu M.H., et al. Elevated aflatoxin and increased risk of hepatocellular carcinoma. Hepatology 24 (1996) 38-42
3. Ueno Y., Nagata S., Tsutsumi T., et al. Detection of microcystins, a blue-green algal hepatotoxin, in drinking water sampled in Haimen and Fusui, endemic areas of primary liver cancer in China, by highly sensitive immunoassay. Carcinogenesis 17 (1996) 1317-1321
4. Tsai J.F., Chuang L.Y., Jeng J.E., et al. Betel quid chewing as a risk factor for hepatocellular carcinoma: a case-control study. Br J Cancer 84 (2001) 709-713
5. Tanaka K., Hirohata T., Takeshita S., et al. Hepatitis B virus, cigarette smoking and alcohol consumption in the development of hepatocellular carcinoma: a case-control study in Fukuoka, Japan. Int J Cancer 51 (1992) 509-514
6. Chen C.-J., Wang L.-Y., and Yu M.-W. Epidemiology of hepatitis B virus infection in the Asia-Pacific region. J Gastroenterol Hepatol 15 (2000) 3-6
7. Moriya T., Koyama T., Tanaka T., et al. Epidemiology of hepatitis C virus in Japan. Intervirology 42 (1999) 2-3
8. Sun C.A., Chen H.C., Lu S.N., et al. Persistent hyperendemicity of hepatitis C virus infection in Taiwan: the important role of iatrogenic factors. J Med Virol 65 (2001) 30-34
9. Brechot C., Nalpas B., and Feitelson M.A. Interactions between alcohol and hepatitis viruses in the liver. Clin Lab Med 16 (1996) 273-287
10. Schiff E.R. Hepatitis C and alcohol. Hepatology 26 (1997) 39-42
11. Hassan M.M., Hwang L.-Y., Hatten C.J., et al. Risk factors for hepatocellular carcinoma: synergism of alcohol with viral hepatitis and diabetes mellitus. Hepatology 36 (2002) 1206-1213
12. Kao J.H., and Chen D.S. Global control of hepatitis B virus infection. Lancet Infect Dis 2 (2002) 395-403
13. Jan C.F., Chen C.J., and Chen H.H. Causes of increased mortality from hepatocellular carcinoma in high incidence country: Taiwan experience. J Gastroenterol Hepatol 20 (2005) 521-526
14. World Bank. Data and statistics: country classification. http://go.worldbank.org/K2CKM78CC0 (accessed May 3, 2009).
15. World Health Organization. Executive summary of the national cancer control programmes: policies and managerial guidelines (2002), World Health Organization, Geneva, Switzerland
16. Anderson B.O., Yip C.H., Smith R.A., et al. Guideline implementation for breast healthcare in low-income and middle-income countries: overview of the Breast Health Global Initiative Global Summit 2007. Cancer 113 suppl (2008) 2221-2243
17. Philips B., Ball C., Sackett D., et al. Oxford Centre for Evidence-based Medicine Levels of Evidence. http://www.cebm.net/index.aspx?o=1025 (accessed May 3, 2009).
18. Yao J.L. Perinatal transmission of hepatitis B virus infection and vaccination in China. Gut 38 suppl 2 (1996) 37-38
19. Stevens C.E., Beasley R.P., Tsui J., and Lee W.C. Vertical transmission of hepatitis B antigen in Taiwan. N Engl J Med 292 (1975) 771-774
20. Okada K., Kamiyama I., Inomata M., Imai M., and Miyakawa Y. E antigen and anti-e in the serum of asymptomatic carrier mothers as indicators of positive and negative transmission of hepatitis B virus to their infants. N Engl J Med 294 (1976) 746-749
21. Beasley R.P., Trepo C., Stevens C.E., and Szmuness W. The e antigen and vertical transmission of hepatitis B surface antigen. Am J Epidemiol 105 (1977) 94-98
22. Lee C.F., Gong Y., Brok J., et al. Effect of hepatitis B immunisation in newborn infants of mothers positive for hepatitis B surface antigen: systematic review and meta-analysis. BMJ 332 (2006) 328-336
23. Hsu H.M., Lu C.F., Lee S.C., Lin S.R., and Chen D.S. Seroepidemiologic survey for hepatitis B virus infection in Taiwan: the effect of hepatitis B mass immunisation. J Infect Dis 179 (1999) 367-370
24. Poovorawan Y., Theamboonlers A., Vimolket T., et al. Impact of hepatitis B immunisation as part of the EPI. Vaccine 19 (2000) 943-949
25. Goh K.T. Prevention and control of hepatitis B virus infection in Singapore. Ann Acad Med Singapore 26 (1997) 671-681
26. Chang M.H., Chen C.J., Lai M.S., et al. Universal hepatitis B vaccination in Taiwan and the incidence of hepatocellular carcinoma in children. Taiwan Childhood Hepatoma Study Group. N Engl J Med 336 (1997) 1855-1859
27. Chang M.H., Shau W.Y., Chen C.J., et al. Hepatitis B vaccination and hepatocellular carcinoma rates in boys and girls. JAMA 284 (2000) 3040-3042
28. Schreiber G.B., Busch M.P., Kleinman S.H., et al. The risk of transfusion-transmitted viral infections. N Engl J Med 334 (1996) 1685-1690
29. Wang J.T., Lee C.Z., Chen P.J., et al. Transfusion-transmitted HBV infection in an endemic area: the necessity of more sensitive screening for HBV carriers. Transfusion 42 (2002) 1592-1597
30. Shang G.F., Seed C.R., Wang F., et al. Residual risk of transfusion-transmitted viral infections in Shenzhen, China, 2001 through 2004. Transfusion 47 (2007) 529-539
31. Freudenberg N., Galea S., Fahs M., et al. Changing corporate practices to reduce cancer disparities. J Health Care Poor Underserved 19 (2008) 26-40
32. Camma C., Giunta M., Andreone P., et al. Inteferon and prevention of hepatocellular carcinoma in viral cirrhosis: an evidence-based approach. J Hepatol 34 (2001) 593-602
33. Chow W.C., Cooksley G., Piratvisuth T., et al. A practical tool to predict response to peginterferon alfa-2a in Asian patients with HBeAg-positive chronic hepatitis B. J Gastroenterol Hepatol 21 suppl (2006) 32
34. Liaw Y.F., Sung J.Y., Chow W.C., et al. Lamivudine for patients with chronic hepatitis B and advanced liver disease. N Engl J Med 351 (2004) 1521-1531
35. Omata M., Yoshida H., Shiratori Y., et al. Prevention of hepatocelluar carcinoma and its recurrence in chronic hepatitis C patients by interferon therapy. Clin Gastroenterol Hepatol 3 (2005) 141-143
36. Arguedas M.R., Chen V.K., Eloubeidi M.A., et al. Screening for hepato-cellular carcinoma in patients with hepatitis C cirrhosis: a cost-utility analysis. Am J Gastroenterol 98 (2003) 679-690
37. Zhang B.H., Yang B.H., Tang Z.Y., et al. Randomized controlled trial of screening for hepatocellular carcinoma. J Cancer Res Clin Oncol 130 (2004) 417-422
38. Colli A., Fraquelli M., Casazza G., et al. Accuracy of ultrasonography, spiral CT, magnetic resonance, and alpha-fetoprotein in diagnosing hepatocellular carcinoma: a systematic review. Am J Gastroenterol 101 (2006) 513-523
39. Parikh P., Malhotra H., and Jelic S. Hepatocellular carcinoma: ESMO Clinical recommendations for diagnosis, treatment and follow-up. Ann Oncol 19 suppl 2 (2008) 27-28
40. Silva M.A., Hegab B., Hyde C., et al. Needle track seeding following biopsy of liver lesions in the diagnosis of hepatocellular cancer: a systematic review and meta-analysis. Gut 57 (2008) 1592-1596
41. Katyal S., Oliver J.H., Peterson M.S., et al. Extrahepatic metastases of hepatocellular carcinoma. Radiology 216 (2000) 698-703
42. Vauthey J.N., Ribero D., Abdalla E.K., et al. Outcomes of liver transplantation in 490 patients with hepatocellular carcinoma: validation of a uniform staging after surgical treatment. J Am Coll Surg 204 (2007) 1016-1027
43. Lu W.P., Dong J.H., Huang Z.Q., et al. Comparison of four current staging systems for Chinese patients with hepatocellular carcinoma undergoing curative resection: Okuda, CLIP, TNM and CUPI. J Gastroenterol Hepatol 23 (2008) 1874-1878
44. Cho Y.K., Chung J.W., Kim J.K., et al. Comparison of 7 staging systems for patients with hepatocellular carcinoma undergoing transarterial chemoembolization. Cancer 112 (2008) 352
45. Georgiades C.S., Liapi E., Frangakis C., et al. Prognostic accuracy of 12 liver staging systems in patients with unresectable hepatocellular carcinoma treated with transarterial chemoembolization. J Vasc Interv Radiol 17 (2006) 1619-1624
46. Leung T.W., Tang A.M., Zee B., et al. Construction of the Chinese University Prognostic Index for hepatocellular carcinoma and comparison with the TNM, Okuda and CLIP staging systems: a study based on 926 patients. Cancer 94 (2002) 1760-1769
47. Leung T.W., Mo F., Leow C.K., et al. Multicenter validation of the Chinese University Prognostic Index (CUPI) for hepatocellular carcinoma (HCC). Proc Am Soc Clin Oncol 22 (2003) (abstr 1040).
48. Yeh C.N., Lee W.C., Chen M.F., et al. Hepatic resection and prognosis for patients with hepatocellular carcinoma larger than 10 cm: two decades of experience at Chang Gung memorial hospital. Ann Surg Oncol 10 (2003) 1070-1076
49. Poon R.T., Ng I.O., Fan S.T., et al. Clinicopathologic features of long-term survivors and disease-free survivors after resection of hepatocellular carcinoma: a study of a prospective cohort. J Clin Oncol 19 (2001) 3037-3044
50. Imamura H., Seyama Y., Kokudo N., et al. One thousand fifty-six hepatectomies without mortality in 8 years. Arch Surg 138 (2003) 1198-1206
51. Poon R.T., and Fan S.T. Assessment of hepatic reserve for indication of hepatic resection: how I do it. J Hepatobiliary Pancreat Surg 12 (2005) 31-37
52. Fan S.T., Lo C.M., Liu C.L., et al. Hepatectomy for hepatocellular carcinoma: toward zero hospital deaths. Ann Surg 229 (1999) 322-330
53. Poon R.T., Fan S.T., Lo C.M., et al. Long-term survival and pattern of recurrence after resection of small hepatocellular carcinoma in patients with preserved liver function. Ann Surg 235 (2002) 373-382
54. Poon R.T., Fan S.T., Lo C.M., et al. Difference in tumor invasiveness in cirrhotic patients with hepatocellular carcinoma fulfilling the Milan Criteria treated by resection and transplantation. Ann Surg 245 (2007) 51-58
55. Cha C.H., Ruo L., Fong Y., et al. Resection of hepatocellular carcinoma in patients otherwise eligible for transplantation. Ann Surg 238 (2003) 315-321
56. Llovet J.M., Fuster J., Bruix J., et al. Intention-to-treat analysis of surgical treatment for early hepatocellular carcinoma: resection versus transplantation. Hepatology 30 (1999) 1434-1440
57. Mazzaferro V., Regalia E., Doci R., et al. Liver transplantation for the treatment of small hepatocellular carcinomas in patients with cirrhosis. N Engl J Med 334 (1996) 693-699
58. Yao F.Y., Ferrell L., Bass N.M., et al. Liver transplantation for hepatocellular carcinoma: expansion of the tumor size limits does not adversely impact survival. Hepatology 33 (2001) 1394-1403
59. Mazzaferro V., Llovet J.M., Miceli R., et al. Predicting survival after liver transplantation in patients with hepatocellular carcinoma beyond the Milan criteria: a retrospective, exploratory analysis. Lancet Oncol 10 (2009) 35-43
60. Duffy J.P., Vardanian A., Benjamin E., et al. Liver transplantation criteria for hepatocellular carcinoma should be expanded: a 22-year experience with 467 patients at UCLA. Ann Surg 246 (2007) 502-511
61. Lau W.Y., Ho S.K., Yu S.C., et al. Salvage surgery following downstaging of unresectable hepatocellular carcinoma. Ann Surg 240 (2004) 299-305
62. Ang M.K., Poon D., Foo K.F., et al. A new chemoimmunotherapy regimen (OXAFI) for advanced hepatocellular carcinoma. Hematol Oncol Stem Cel Ther 1 (2008) 159-165
63. Samuel M., Chow P.K., Shih-Yen E.C., Machin D., and Soo K.C. Neoadjuvant and adjuvant therapy for surgical resection of hepatocellular carcinoma. Cochrane Database Syst Rev 1 (2009) CD001199.
64. Sasaki A., Iwashita Y., Shibata K., et al. Preoperative transcatheter arterial chemoembolization reduces long-term survival rate after hepatic resection for resectable hepatocellular carcinoma. Eur J Surg Oncol 32 (2006) 773-779
65. Lau W.Y., Lai E.C., Leung T.W., et al. Adjuvant Intra-arterial Iodine-131-labeled Lipiodol for resectable hepatocellular carcinoma: a prospective randomized trial-update on 5-year and 10-year survival. Ann Surg 247 (2008) 43-48
66. Shiina S., Teratani T., Obi S., et al. A randomized controlled trial of radiofrequency ablation with ethanol injection for small hepatocellular carcinoma. Gastroenterology 129 (2005) 122-130
67. Marelli L., Stigliano R., Triantos C., et al. Transarterial therapy for hepatocellular carcinoma: which technique is more effective? A systematic review of cohort and randomized studies. Cardiovasc Intervent Radiol 30 (2007) 6-25
68. Lo C.M., Ngan H., Tso W.K., et al. Randomized controlled trial of transarterial lipiodol chemoembolization for unresectable hepatocellular carcinoma. Hepatology 35 (2002) 1164-1171
69. Llovet J.M., Real M.I., Montana X., et al. Arterial embolisation or chemoembolisation versus symptomatic treatment in patients with unresectable hepatocellular carcinoma: a randomised controlled trial. Lancet 359 (2002) 1734-1739
70. Llovet J.M., and Bruix J. Systematic review of randomized trials for unresectable hepatocellular carcinoma: chemoembolization improves survival. Hepatology 37 (2003) 429-442
71. Chan A.O., Yuen M.F., Hui C.K., et al. A prospective study regarding the complications of transcatheter intraarterial lipiodol chemoembolization in patients with hepatocellular carcinoma. Cancer 94 (2002) 1747-1752
72. Chapman W.C., Doyle M.M., Stuart J.E., et al. Outcomes of neoadjuvant transarterial chemoembolization to downstage hepatocellular carcinoma before liver transplantation. Ann Surg 248 (2008) 617-625
73. Decaens T., Roudot-Thoraval F., Bresson-Hadni S., et al. Impact of pretransplantation transarterial chemoembolization on survival and recurrence after liver transplantation for hepatocellular carcinoma. Liver Transpl 11 (2005) 767-775
74. Geschwind J.F., Salem R., Carr B.I., et al. Yttrium-90 microspheres for the treatment of hepatocellular carcinoma. Gastroenterology 127 5 suppl 1 (2004) 194-205
75. Lau W.Y., Ho S., Leung T.W., et al. Selective internal radiation therapy for nonresectable hepatocellular carcinoma with intraarterial infusion of 90yttrium microspheres. Int J Radiat Oncol Biol Phys 40 (1998) 583-592
76. Llovet J.M., Ricci S., Mazzaferro V., et al. Sorafenib in advanced hepatocellular carcinoma. N Engl J Med 359 (2008) 378-390
77. Cheng A.L., Kang Y.K., Chen Z., et al. Efficacy and safety of sorafenib in patients in the Asia-Pacific region with advanced hepatocellular carcinoma: a phase III randomised, double-blind, placebo-controlled trial. Lancet Oncol 10 (2009) 25-34